Please Wait.....
Report
Stem cell therapy Market By Cell Source (Adipose Tissue-Derived Mesenchymal Stem Cells, Bone Marrow-Derived Mesenchymal Stem Cells, Cord Blood/Embryonic Stem Cells, Other), By Application (Cancer, Musculoskeletal Disorder, Wounds and Injuries, Cardiovascular Disease, Other), By Type (Allogeneic Transplants, Autologous Transplants): Global Opportunity Analysis and Industry Forecast, 2021-2031
Market Report I 2022-09-01 I 274 Pages I Allied Market Research
The global stem cell therapy market was valued at $205.12 million in 2021, and is projected to reach $928.64 million by 2031, registering a CAGR of 16.2% from 2022 to 2031.
The stem cell therapy is a promising strategy for regeneration of damaged organs, tissues or functions through the transplantation of stem cells. The cell therapy involves the direct administration of cells into the body for healing purposes. The units of therapy in this approach are single cells. It has been established as a useful therapy for hematologic malignancies and some solid tumors. However, some of the patients still die in allogeneic stem cell transplantation because T-lymphocytes cause fatal GVHD, and many are not cured in autologous stem cell transplantation as the disease recurs post-stem cell transplantation. Hematopoietic stem cell therapies provide methods for inducing lifelong tolerance to xenografts or allow novel treatment of autoimmune diseases, whereas the research and use of nonhematopoietic stem cells help minimize the toxicities of cancer therapy or cure non-malignant disorders.
The global stem cell therapy market is anticipated to show significant market growth during the forecast period, owing to increase in demand for stem cell therapy, increase in government support for R&D activities and increase in healthcare expenditure. Furthermore, increase in prevalence of diseases such as cancer, and new product launches associated with stem cell therapy are considerably contributing toward the market growth. However, limitations on use of embryonic stem cells due to ethical concerns and high cost of stem cell therapy are negatively impacting the market growth.Conversely, surge in the applications of induced pluripotent stem cells in embryonic stem cell therapy offers the lucrative opportunities for the growth of the market.
The global stem cell therapy market is segmented on the basis of cell source, application, type and region. Based on cell source, the market is classified into adipose tissue-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, cord blood/embryonic stem cells, other. Based on application, the market is classified into cancer, musculoskeletal disorders, wounds and injuries, cardiovascular diseases, gastrointestinal diseases, other. Based on type, the market is classified into allogeneic transplants and autologous transplants.Furthermore, the allogeneic transplants segment is sub-classified as pediatric and adult. Also, the autologous transplants segment is sub-classified as pediatric and adult. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
The major companies profiled in the report include Allele Biotechnology and Pharmaceuticals, Inc., Astellas Pharma Inc, Fujifilm Holding Corporation (FUJIFILM Cellular Dynamics, Inc.), Mesoblast Ltd, Novadip Biosciences, NuVasive, Inc., Orthofix Holdings, Inc., Smith & Nephew plc, Takeda Pharmaceutical, and U.S. Stem Cell, Inc.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the stem cell therapy market analysis from 2021 to 2031 to identify the prevailing stem cell therapy market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the stem cell therapy market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global stem cell therapy market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Cell Source
- Adipose Tissue-Derived Mesenchymal Stem Cells
- Bone Marrow-Derived Mesenchymal Stem Cells
- Cord Blood/Embryonic Stem Cells
- Other
By Application
- Cancer
- Musculoskeletal Disorder
- Wounds and Injuries
- Cardiovascular Disease
- Other
By Type
- Allogeneic Transplants
- Age
- Pediatric
- Adult
- Autologous Transplants
- Age
- Pediatric
- Adult
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Rest Of Europe
- Asia-Pacific
- Japan
- India
- South Korea
- Rest Of Asia-Pacific
- LAMEA
- Brazil
- Rest Of LAMEA
- Key Market Players
- Allele Biotechnology and Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- Fujifilm Holding Corporation
- Mesoblast Ltd.
- Novadip Biosciences
- NuVasive, Inc.
- Orthofix Holdings, Inc.
- Smith & Nephew plc
- Takeda Pharmaceutical Company Ltd
- U.S. Stem Cell, Inc.
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: STEM CELL THERAPY MARKET, BY CELL SOURCE
4.1 Overview
4.1.1 Market size and forecast
4.2 Adipose Tissue-Derived Mesenchymal Stem Cells
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Bone Marrow-Derived Mesenchymal Stem Cells
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Cord Blood/Embryonic Stem Cells
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Other
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
CHAPTER 5: STEM CELL THERAPY MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Cancer
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Musculoskeletal Disorder
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Wounds and Injuries
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Cardiovascular Disease
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Other
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
CHAPTER 6: STEM CELL THERAPY MARKET, BY TYPE
6.1 Overview
6.1.1 Market size and forecast
6.2 Allogeneic Transplants
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.2.4 Allogeneic Transplants Stem cell therapy Market by Age
6.2.4.1 Pediatric Market size and forecast, by region
6.2.4.2 Adult Market size and forecast, by region
6.3 Autologous Transplants
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.3.4 Autologous Transplants Stem cell therapy Market by Age
6.3.4.1 Pediatric Market size and forecast, by region
6.3.4.2 Adult Market size and forecast, by region
CHAPTER 7: STEM CELL THERAPY MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Cell Source
7.2.3 North America Market size and forecast, by Application
7.2.4 North America Market size and forecast, by Type
7.2.4.1 North America Allogeneic Transplants Stem cell therapy Market by Age
7.2.4.2 North America Autologous Transplants Stem cell therapy Market by Age
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Cell Source
7.2.5.1.2 Market size and forecast, by Application
7.2.5.1.3 Market size and forecast, by Type
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Cell Source
7.2.5.2.2 Market size and forecast, by Application
7.2.5.2.3 Market size and forecast, by Type
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Cell Source
7.3.3 Europe Market size and forecast, by Application
7.3.4 Europe Market size and forecast, by Type
7.3.4.1 Europe Allogeneic Transplants Stem cell therapy Market by Age
7.3.4.2 Europe Autologous Transplants Stem cell therapy Market by Age
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Cell Source
7.3.5.1.2 Market size and forecast, by Application
7.3.5.1.3 Market size and forecast, by Type
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Cell Source
7.3.5.2.2 Market size and forecast, by Application
7.3.5.2.3 Market size and forecast, by Type
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Cell Source
7.3.5.3.2 Market size and forecast, by Application
7.3.5.3.3 Market size and forecast, by Type
7.3.5.4 Rest of Europe
7.3.5.4.1 Market size and forecast, by Cell Source
7.3.5.4.2 Market size and forecast, by Application
7.3.5.4.3 Market size and forecast, by Type
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Cell Source
7.4.3 Asia-Pacific Market size and forecast, by Application
7.4.4 Asia-Pacific Market size and forecast, by Type
7.4.4.1 Asia-Pacific Allogeneic Transplants Stem cell therapy Market by Age
7.4.4.2 Asia-Pacific Autologous Transplants Stem cell therapy Market by Age
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Cell Source
7.4.5.1.2 Market size and forecast, by Application
7.4.5.1.3 Market size and forecast, by Type
7.4.5.2 India
7.4.5.2.1 Market size and forecast, by Cell Source
7.4.5.2.2 Market size and forecast, by Application
7.4.5.2.3 Market size and forecast, by Type
7.4.5.3 South Korea
7.4.5.3.1 Market size and forecast, by Cell Source
7.4.5.3.2 Market size and forecast, by Application
7.4.5.3.3 Market size and forecast, by Type
7.4.5.4 Rest of Asia-Pacific
7.4.5.4.1 Market size and forecast, by Cell Source
7.4.5.4.2 Market size and forecast, by Application
7.4.5.4.3 Market size and forecast, by Type
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Cell Source
7.5.3 LAMEA Market size and forecast, by Application
7.5.4 LAMEA Market size and forecast, by Type
7.5.4.1 LAMEA Allogeneic Transplants Stem cell therapy Market by Age
7.5.4.2 LAMEA Autologous Transplants Stem cell therapy Market by Age
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Cell Source
7.5.5.1.2 Market size and forecast, by Application
7.5.5.1.3 Market size and forecast, by Type
7.5.5.2 Rest of LAMEA
7.5.5.2.1 Market size and forecast, by Cell Source
7.5.5.2.2 Market size and forecast, by Application
7.5.5.2.3 Market size and forecast, by Type
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Allele Biotechnology and Pharmaceuticals, Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Astellas Pharma Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Fujifilm Holding Corporation
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Mesoblast Ltd.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Novadip Biosciences
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 NuVasive, Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Orthofix Holdings, Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Smith & Nephew plc
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Takeda Pharmaceutical Company Ltd
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 U.S. Stem Cell, Inc.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 2. STEM CELL THERAPY MARKET, FOR ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. STEM CELL THERAPY MARKET, FOR BONE MARROW-DERIVED MESENCHYMAL STEM CELLS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MESENCHYMAL STEM CELLS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. STEM CELL THERAPY MARKET, FOR CORD BLOOD/EMBRYONIC STEM CELLS, BY REGION, 2021-2031 ($MILLION)
TABLE 7. STEM CELL THERAPY MARKET FOR CORD BLOOD/EMBRYONIC STEM CELLS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. STEM CELL THERAPY MARKET, FOR OTHER, BY REGION, 2021-2031 ($MILLION)
TABLE 9. STEM CELL THERAPY MARKET FOR OTHER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. GLOBAL STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 11. STEM CELL THERAPY MARKET, FOR CANCER, BY REGION, 2021-2031 ($MILLION)
TABLE 12. STEM CELL THERAPY MARKET FOR CANCER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. STEM CELL THERAPY MARKET, FOR MUSCULOSKELETAL DISORDER, BY REGION, 2021-2031 ($MILLION)
TABLE 14. STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. STEM CELL THERAPY MARKET, FOR WOUNDS AND INJURIES, BY REGION, 2021-2031 ($MILLION)
TABLE 16. STEM CELL THERAPY MARKET FOR WOUNDS AND INJURIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. STEM CELL THERAPY MARKET, FOR CARDIOVASCULAR DISEASE, BY REGION, 2021-2031 ($MILLION)
TABLE 18. STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. STEM CELL THERAPY MARKET, FOR OTHER, BY REGION, 2021-2031 ($MILLION)
TABLE 20. STEM CELL THERAPY MARKET FOR OTHER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 22. STEM CELL THERAPY MARKET, FOR ALLOGENEIC TRANSPLANTS, BY REGION, 2021-2031 ($MILLION)
TABLE 23. STEM CELL THERAPY MARKET FOR ALLOGENEIC TRANSPLANTS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 24. GLOBAL ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 25. STEM CELL THERAPY MARKET, FOR PEDIATRIC, BY REGION, 2021-2031 ($MILLION)
TABLE 26. STEM CELL THERAPY MARKET, FOR ADULT, BY REGION, 2021-2031 ($MILLION)
TABLE 27. STEM CELL THERAPY MARKET, FOR AUTOLOGOUS TRANSPLANTS, BY REGION, 2021-2031 ($MILLION)
TABLE 28. STEM CELL THERAPY MARKET FOR AUTOLOGOUS TRANSPLANTS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. GLOBAL AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 30. STEM CELL THERAPY MARKET, FOR PEDIATRIC, BY REGION, 2021-2031 ($MILLION)
TABLE 31. STEM CELL THERAPY MARKET, FOR ADULT, BY REGION, 2021-2031 ($MILLION)
TABLE 32. STEM CELL THERAPY MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 33. NORTH AMERICA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 34. NORTH AMERICA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 35. NORTH AMERICA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 36. NORTH AMERICA ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 37. NORTH AMERICA AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 38. NORTH AMERICA STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 39. U.S. STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 40. U.S. STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 41. U.S. STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 42. CANADA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 43. CANADA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 44. CANADA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 45. EUROPE STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 46. EUROPE STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 47. EUROPE STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 48. EUROPE ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 49. EUROPE AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 50. EUROPE STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 51. GERMANY STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 52. GERMANY STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 53. GERMANY STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 54. FRANCE STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 55. FRANCE STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 56. FRANCE STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 57. UK STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 58. UK STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 59. UK STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 60. REST OF EUROPE STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 61. REST OF EUROPE STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 62. REST OF EUROPE STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 63. ASIA-PACIFIC STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 69. JAPAN STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 70. JAPAN STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 71. JAPAN STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 72. INDIA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 73. INDIA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 74. INDIA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 75. SOUTH KOREA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 76. SOUTH KOREA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 77. SOUTH KOREA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 78. REST OF ASIA-PACIFIC STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 79. REST OF ASIA-PACIFIC STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 80. REST OF ASIA-PACIFIC STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 81. LAMEA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 82. LAMEA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 83. LAMEA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 84. LAMEA ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 85. LAMEA AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)
TABLE 86. LAMEA STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 87. BRAZIL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 88. BRAZIL STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 89. BRAZIL STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 90. REST OF LAMEA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)
TABLE 91. REST OF LAMEA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 92. REST OF LAMEA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 93.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 94.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.: OPERATING SEGMENTS
TABLE 95.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 96.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.: NET SALES,
TABLE 97.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.: KEY STRATERGIES
TABLE 98.ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
TABLE 99.ASTELLAS PHARMA INC.: OPERATING SEGMENTS
TABLE 100.ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
TABLE 101.ASTELLAS PHARMA INC.: NET SALES,
TABLE 102.ASTELLAS PHARMA INC.: KEY STRATERGIES
TABLE 103.FUJIFILM HOLDING CORPORATION: COMPANY SNAPSHOT
TABLE 104.FUJIFILM HOLDING CORPORATION: OPERATING SEGMENTS
TABLE 105.FUJIFILM HOLDING CORPORATION: PRODUCT PORTFOLIO
TABLE 106.FUJIFILM HOLDING CORPORATION: NET SALES,
TABLE 107.FUJIFILM HOLDING CORPORATION: KEY STRATERGIES
TABLE 108.MESOBLAST LTD.: COMPANY SNAPSHOT
TABLE 109.MESOBLAST LTD.: OPERATING SEGMENTS
TABLE 110.MESOBLAST LTD.: PRODUCT PORTFOLIO
TABLE 111.MESOBLAST LTD.: NET SALES,
TABLE 112.MESOBLAST LTD.: KEY STRATERGIES
TABLE 113.NOVADIP BIOSCIENCES: COMPANY SNAPSHOT
TABLE 114.NOVADIP BIOSCIENCES: OPERATING SEGMENTS
TABLE 115.NOVADIP BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 116.NOVADIP BIOSCIENCES: NET SALES,
TABLE 117.NOVADIP BIOSCIENCES: KEY STRATERGIES
TABLE 118.NUVASIVE, INC.: COMPANY SNAPSHOT
TABLE 119.NUVASIVE, INC.: OPERATING SEGMENTS
TABLE 120.NUVASIVE, INC.: PRODUCT PORTFOLIO
TABLE 121.NUVASIVE, INC.: NET SALES,
TABLE 122.NUVASIVE, INC.: KEY STRATERGIES
TABLE 123.ORTHOFIX HOLDINGS, INC.: COMPANY SNAPSHOT
TABLE 124.ORTHOFIX HOLDINGS, INC.: OPERATING SEGMENTS
TABLE 125.ORTHOFIX HOLDINGS, INC.: PRODUCT PORTFOLIO
TABLE 126.ORTHOFIX HOLDINGS, INC.: NET SALES,
TABLE 127.ORTHOFIX HOLDINGS, INC.: KEY STRATERGIES
TABLE 128.SMITH & NEPHEW PLC: COMPANY SNAPSHOT
TABLE 129.SMITH & NEPHEW PLC: OPERATING SEGMENTS
TABLE 130.SMITH & NEPHEW PLC: PRODUCT PORTFOLIO
TABLE 131.SMITH & NEPHEW PLC: NET SALES,
TABLE 132.SMITH & NEPHEW PLC: KEY STRATERGIES
TABLE 133.TAKEDA PHARMACEUTICAL COMPANY LTD: COMPANY SNAPSHOT
TABLE 134.TAKEDA PHARMACEUTICAL COMPANY LTD: OPERATING SEGMENTS
TABLE 135.TAKEDA PHARMACEUTICAL COMPANY LTD: PRODUCT PORTFOLIO
TABLE 136.TAKEDA PHARMACEUTICAL COMPANY LTD: NET SALES,
TABLE 137.TAKEDA PHARMACEUTICAL COMPANY LTD: KEY STRATERGIES
TABLE 138.U.S. STEM CELL, INC.: COMPANY SNAPSHOT
TABLE 139.U.S. STEM CELL, INC.: OPERATING SEGMENTS
TABLE 140.U.S. STEM CELL, INC.: PRODUCT PORTFOLIO
TABLE 141.U.S. STEM CELL, INC.: NET SALES,
TABLE 142.U.S. STEM CELL, INC.: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1.STEM CELL THERAPY MARKET SEGMENTATION
FIGURE 2.STEM CELL THERAPY MARKET,2021-2031
FIGURE 3.STEM CELL THERAPY MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.STEM CELL THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.STEM CELL THERAPY MARKET,BY CELL SOURCE,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS STEM CELL THERAPY MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF BONE MARROW-DERIVED MESENCHYMAL STEM CELLS STEM CELL THERAPY MARKET,2021-2031(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF CORD BLOOD/EMBRYONIC STEM CELLS STEM CELL THERAPY MARKET,2021-2031(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHER STEM CELL THERAPY MARKET,2021-2031(%)
FIGURE 17.STEM CELL THERAPY MARKET,BY APPLICATION,2021(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CANCER STEM CELL THERAPY MARKET,2021-2031(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDER STEM CELL THERAPY MARKET,2021-2031(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF WOUNDS AND INJURIES STEM CELL THERAPY MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF CARDIOVASCULAR DISEASE STEM CELL THERAPY MARKET,2021-2031(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF OTHER STEM CELL THERAPY MARKET,2021-2031(%)
FIGURE 23.STEM CELL THERAPY MARKET,BY TYPE,2021(%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET,2021-2031(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET,2021-2031(%)
FIGURE 26.STEM CELL THERAPY MARKET BY REGION,2021
FIGURE 27.U.S. STEM CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 28.CANADA STEM CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 29.GERMANY STEM CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 30.FRANCE STEM CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 31.UK STEM CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 32.REST OF EUROPE STEM CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 33.JAPAN STEM CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 34.INDIA STEM CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 35.SOUTH KOREA STEM CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 36.REST OF ASIA-PACIFIC STEM CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 37.BRAZIL STEM CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 38.REST OF LAMEA STEM CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 39. TOP WINNING STRATEGIES, BY YEAR
FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 42.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 43.COMPETITIVE DASHBOARD
FIGURE 44.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 45.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC..: NET SALES ,($MILLION)
FIGURE 46.ASTELLAS PHARMA INC..: NET SALES ,($MILLION)
FIGURE 47.FUJIFILM HOLDING CORPORATION.: NET SALES ,($MILLION)
FIGURE 48.MESOBLAST LTD..: NET SALES ,($MILLION)
FIGURE 49.NOVADIP BIOSCIENCES.: NET SALES ,($MILLION)
FIGURE 50.NUVASIVE, INC..: NET SALES ,($MILLION)
FIGURE 51.ORTHOFIX HOLDINGS, INC..: NET SALES ,($MILLION)
FIGURE 52.SMITH & NEPHEW PLC.: NET SALES ,($MILLION)
FIGURE 53.TAKEDA PHARMACEUTICAL COMPANY LTD.: NET SALES ,($MILLION)
FIGURE 54.U.S. STEM CELL, INC..: NET SALES ,($MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security